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study employs FDG-PET/CT to study the response patterns in 
normal lung and to potentially identify cytotoxic effects. 
Materials and Methods: This project included 22 patients 
with advanced-stage non-small cell lung cancer, participating 
in a phase II trial of combined radiation and erlotinib-
therapy. The patients underwent three PET-CT examinations; 
pre-therapy, mid-therapy, and six weeks after fractionated 
radiotherapy (3Gy x 10). Nine patients received fractionated 
RT only, while 13 patients received erlotinib (150 mg p.o. 
daily) and fractionated RT. For each patient, lung was 
delineated in the planning CT before the initiation of 
treatment. The RT dose matrix was co-registered with the 
PET/CT image series. The FDG-uptake distribution, in terms 
of the standardized uptake value (SUV), was obtained for 
lung from all PET-CT examinations. In order to identify the 
association between SUV and RT dose, SUVmean was calculated 
in dose bins of 0.5 Gy. Linear regression was applied to 
extract trends in the dose-SUV relationship. The effect of 
erlotinib was investigated by separating patients into 
erlotinib receiving and a non-erlotinib receiving groups. 
Results: A positive linear relationship was identified between 
SUV and RT dose in the lung at both mid- and post-therapy, 
considering all patients. A significant increase (15%) in FDG-
uptake at all dose levels was observed from mid- to post-
therapy. Separating patients based on erlotinib treatment, a 
positive correlation between SUV and RT dose was identified 
for both groups at mid-therapy. However, the FDG-uptake 
was significantly higher (16%) in the erlotinib-receiving 
group. At post-therapy, patients receiving erlotinib again had 
a significantly elevated FDG-uptake in lung compared to non-
erlotinib receiving patients, but the association with RT dose 
for erlotinib-receiving patients was absent. 
Conclusions: Normal lung glucose metabolism positively 
correlated with RT dose during the first week of treatment. 
This could indicate RP in the lung. Erlotinib increased the 
FDG uptake in the lung compared to RT only. This study 
indicates that more detailed follow-up of lung toxicity in 
patients undergoing erlotinib therapy is required. Also, 
deeper mechanistic studies into the biological action of RT 
and erlotinib in the healthy lung are warranted. 
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Purpose/Objective: The aim of the study was to evaluate the 
interest of weekly Cone Beam CT (CBCT) to predict the risk 
of local recurrence and survival in case of radio-
chemotherapy (RT-CT) for locally advanced NSCLC (LA-
NSCLC). 
Materials and Methods: Between August 2011 and March 
2014, a series of 21 patients (pts) with a mean age of 67 
years (49-81 years) and presenting a LA-NSCLC (stage IIIA or 
IIIB) were treated by RT-CT. The total dose was 66 Gy at 2.2 
Gy/fraction over 6 weeks delivered by IMRT and IGRT using 
CBCT. Weekly CBCT were used to delineate the primary 
tumor (TV), excluding the mediastinal lymph nodes. The 
response during treatment was quantified by the ratio 
between the primary TV delineated in the weekly CBCT and 
the primary TV delineated in the planning CT. Recurrence 
after treatment was evaluated by 18 Fluoro-deoxy-glucose 
PET and CT scan, performed every 3 months during the first 
two years of follow up. Cox regression model was used to test 
the impact of TV ratio, as continuous values, in the risk of 
local recurrence and death. ROC analysis was used to identify 
TV ratio threshold values. 
Results: The median follow up was 16 months (6-33 months). 
Ten pts (47.6%) presented local failure (LF). The risk of local 
failure at 18 months was 54 % (CI 95%: 30-78%). The OS rate 
at 18 months was 85% (CI 95%: 70-100%). The mean (range) 
TV ratio at week 1, 2, 3, 4, 5 and 6 were: 0.92, (0.5-1.9), 
0.82 (0.3-1.45), 0.75 (0.25-1.42), 0.67 (0.18-1.4), 0.6 (0.15-
1.5) and 0.53 (0.13-0.9) respectively, corresponding to a 
mean tumor regression during treatment of 8% per week. In 
univariate analysis, TV ratios, as continuous values, at the 
fifth and sixth week were predictive of both local failure and 
death (p≤0.04). TV ratio at the fourth week was predictive of 
local failure only (p=0.02). Threshold value of TV ratio 
between 0.7 and 0.8 appears particularly discriminant. 
Conclusions: Monitoring TV in weekly CBCT during RT-CT for 
LA-NSCLC appears useful to predict the risk of recurrence and 
death, identifying pts candidates for treatment 
intensification. A larger series is needed to confirm these 
results and to perform multivariate analysis.  
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Purpose/Objective: The management of intrapulmonary 
recurrence after lung cancer surgery is a challenging 
proposition because of poor lung function. Stereotactic body 
radiotherapy (SBRT) has achieved a good tumor control with 
preserving lung function. The purpose of this study is to 
evaluate the safety and efficacy of SBRT for recurrent lung 
cancer after surgery. 
Materials and Methods: Between July 2008 and September 
2013, 27 patients with intrapulmonary recurrence after lung 
cancer surgery received SBRT at our institution. We 
conducted a retrospective analysis of all these patients (4 
women and 23 men). The median age was 73 years (range, 50 
to 92 years). The median forced expiratory volume in 1 
second before SBRT was 1820ml (range, 920 to 2520ml). The 
prescribed doses were 48Gy in 4 fractions, 60Gy in 10 
fractions, and 50Gy in 10 fractions. Toxicity was graded via 
RTOG/EORTC late radiation morbidity scoring. Overall 
survival (OS) was calculated by the Kaplan-Meier method. 
Results: The median follow up time from SBRT was 2.0 years. 
All patients completed the planned treatment without severe 
acute adverse event. One patient died due to radiation 
pneumonitis after 7 months from SBRT. One patient had 
grade 3 radiation pneumonitis, and one had grade 2. The 
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median OS from SBRT is 2.2 years (95%CI, 1.2 to 2.7 years), 
and the median OS from surgery is 5.0 years (95%CI, 3.9 to 
6.8 years). 
 
 
 
Conclusions: Our results demonstrate that SBRT after surgery 
brings about a good prognosis with low toxicity. SBRT may be 
a good treatment option for intrapulmonary recurrence after 
lung cancer surgery.  
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Purpose/Objective: Stereotactic Ablative Radiotherapy 
(SABR) has now become a primary option for medically 
inoperable patients with early stage non-small cell lung 
cancer (NSCLC). Many retrospective and prospective studies 
have showed that SABR can achieve local control rates of 
approximately 90%, offering a significant survival advantage 
over conventional radiotherapy with specific survival rates 
comparable to those of surgery. The aim of this retrospective 
study was to evaluated the clinical outcomes in patients 
affected with stage I NSCLC, medically inoperable, treated 
with SABR. 
Materials and Methods: Between 2003 and 2012, 110 
consecutive patients with stage I NSCLC were treated with 
SABR. The median age was 77 years (range 48-96 years). 
Histological/cytological diagnosis was obtained in 56 patients 
(50,9 %). The remaining 54 patients (49.1%) were included in 
the study if both FDG-PET was positive and tumor had 
increased in size at a second CT scan performed at least after 
a three months interval. Eighty-five patients (77.3%) had 
stage IA (T1N0M0 in 48 cases and T1bN0M0 in 37 cases, 
respectively) and 25 patients (22.7%) had stage IB (T2aN0M0), 
according to the 7th edition of the TNM classification and 
staging system for lung cancer. One hundred and three 
patients were medically inoperable because of the presence 
of medical comorbidities, poor pulmonary function or 
advanced age; 7 patients refused surgery. In 98 cases (89%) 
the localization of the tumor was peripheral; in 12 cases 
(11%) the localization was central. All patients were treated 
with 3D-CRT, consisting in 7-12 non-coplanar static fields 
conformed by mean of a multi leaf collimator (MLC). Dose 
and fractionation were chosen depending on size and location 
of the tumor. RTOG score were used for grading acute and 
late toxicity. 
Results:  Median follow-up time was 24.2 months (range 3-
123 months). One-year and 3-year local control was 95% and 
75%, respectively. Forty-one patients (45.1%) had at least one 
failure (local and/or nodal and/or distant), with a median 
time to any recurrence of 18.5 months. Disease free survival 
(DFS) rate at 3 years was 53%. Overall survival (OS) at 3 and 5 
years was 70% and 47%, respectively. Grade 1 acute 
pulmonary toxicity was observed in two patients (1.8%). Late 
pulmonary toxicity was recorded in 7 patients (6.3%) as: G1 in 
3, G2 in 3 and G3 in 1 patients, respectively. Seventy-four 
patients (67.3%) developed late radiological toxicity as: G1 in 
66, G2 in 7 and G3 in 1 patients, respectively. 
Conclusions: The results of this study support the routine use 
of SABR for stage I NSCLC, due to high local control and 
limited toxicity.  
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Purpose/Objective: Several investigators suggest that 
pretreatment blood parameters can be useful in determining 
the prognosis of non-small cell lung cancer (NSCLC). The 
relevance of readily available and commonly recorded blood 
parameters for long-term outcome of curative radio-
chemotherapy for NSCLC is, however, only partially 
determined.  
Materials and Methods: The analysis included 104 patients 
with stage IIIAN2 or III B non-small cell lung cancer (64 
squamous cell, 18 adenocarcinoma, 22 NOS). All patients had 
platin-based induction chemotherapy and radiotherapy with 
curative intent (60-74 Gy, 1,8-2.0 Gy/fraction). Twenty 
routinely recorded parameters from automated blood cell 
counter (blood cell number, mean cell volume, distribution 
width, hemoglobin concentration etc.) as well as erythrocyte 
sedimentation rate (ESR), osteopontin concentration (OP) and 
ratios of those parameters were considered in the analysis. 
Clinical parameters of known prognostic potential were also 
included (age, sex, general performance status, T, N stage, 
smoking history). Univariate and multivariate Cox 
proportional hazard regression model was used to select 
variables that had significant and independent impact on 
overall survival. The model performance was assessed with 
respect to 3-year overall survival by calculating the AUC 
(area under the curve) using ROC analysis. 
